Alkermes (NASDAQ:ALKS) Upgraded at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Alkermes (NASDAQ:ALKS) from a strong sell rating to a sell rating in a research report released on Saturday morning, BidAskClub reports.

ALKS has been the topic of a number of other reports. Stifel Nicolaus lowered their price target on shares of Alkermes from to and set a hold rating on the stock in a report on Thursday, February 13th. JPMorgan Chase & Co. downgraded shares of Alkermes from an overweight rating to a neutral rating and lowered their price target for the stock from $25.00 to $21.00 in a report on Thursday, February 13th. Mizuho assumed coverage on shares of Alkermes in a report on Wednesday, February 5th. They set a neutral rating and a $19.00 price target on the stock. HC Wainwright lowered their price target on shares of Alkermes from $26.00 to $25.00 and set a neutral rating on the stock in a report on Friday, February 14th. Finally, Zacks Investment Research downgraded shares of Alkermes from a strong-buy rating to a hold rating and set a $22.00 price target on the stock. in a report on Thursday, January 2nd. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has given a buy rating to the company. The company has a consensus rating of Hold and a consensus target price of $22.92.

NASDAQ:ALKS opened at $19.77 on Friday. The firm has a market capitalization of $3.19 billion, a P/E ratio of -15.69 and a beta of 1.97. Alkermes has a 1-year low of $16.65 and a 1-year high of $37.75. The company’s fifty day moving average price is $18.69 and its 200-day moving average price is $19.94. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.46 and a quick ratio of 2.20.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.18. The firm had revenue of $412.70 million for the quarter, compared to analyst estimates of $404.45 million. Alkermes had a negative net margin of 16.79% and a positive return on equity of 1.58%. The business’s quarterly revenue was up 30.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.34 earnings per share. Equities analysts anticipate that Alkermes will post -0.38 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new position in Alkermes during the fourth quarter valued at $26,000. TCI Wealth Advisors Inc. purchased a new position in Alkermes during the fourth quarter valued at $41,000. NumerixS Investment Technologies Inc lifted its holdings in Alkermes by 17.5% during the fourth quarter. NumerixS Investment Technologies Inc now owns 7,400 shares of the company’s stock valued at $151,000 after purchasing an additional 1,100 shares in the last quarter. Virtu Financial LLC purchased a new position in Alkermes during the third quarter valued at $210,000. Finally, Laurion Capital Management LP purchased a new position in Alkermes during the fourth quarter valued at $232,000. 94.64% of the stock is currently owned by hedge funds and other institutional investors.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability.

Read More: Are sell-side analysts objective?

Analyst Recommendations for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Greenlight Capital Re  Lifted to “Sell” at BidaskClub
Greenlight Capital Re Lifted to “Sell” at BidaskClub
1-800-Flowers.Com  Raised to “Buy” at BidaskClub
1-800-Flowers.Com Raised to “Buy” at BidaskClub
National Beverage  Lifted to “Hold” at BidaskClub
National Beverage Lifted to “Hold” at BidaskClub
Eidos Therapeutics  Raised to Hold at BidaskClub
Eidos Therapeutics Raised to Hold at BidaskClub
BidaskClub Lowers Eagle Pharmaceuticals  to Strong Sell
BidaskClub Lowers Eagle Pharmaceuticals to Strong Sell
Cel-Sci  Upgraded at BidaskClub
Cel-Sci Upgraded at BidaskClub


 
© 2006-2020 Zolmax.